BiotechTube
DiNABIOS

DiNABIOS

Berlin, Germany· Est.
dinabios.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

DiNABIOS is a Berlin-based biotech company commercializing a 30-year research legacy in Engineered Heart Tissue (EHT) technology. Its core offering is an integrated platform combining 3D human cardiac tissues derived from iPSCs with the DiNAQUBE™ automated measurement system and the DiNALYTIQS™ data analytics software. The company operates both as a service provider (CRO) and a tools vendor, focusing on improving the efficiency and human relevance of cardiac drug safety and efficacy testing. Its mission is to make the human body measurable, one organ at a time.

Cardiovascular

Technology Platform

Integrated platform featuring 3D Engineered Heart Tissues (EHTs) derived from human iPSCs, the DiNAQUBE™ automated AI-driven measurement system for video-optical analysis of tissue contractions, and the DiNALYTIQS™ web-based data analytics software.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

Strong regulatory tailwinds from the FDA Modernization Act 2.0 and global shifts toward human-relevant, non-animal testing models.
Growing demand for predictive cardiotoxicity screening and complex disease modeling in drug development, especially for new therapeutic modalities.
Potential to expand the platform technology to other organ systems beyond the heart.

Risk Factors

Faces competition from established CROs and numerous startups in the organ-on-a-chip and stem cell assay space.
Requires significant validation and adoption by risk-averse pharmaceutical R&D departments.
As a young, private company, it is dependent on external funding and faces execution risks in scaling technology and sales.

Competitive Landscape

Competes in the preclinical tools and services market against large CROs (e.g., Charles River, LabCorp) offering standard assays, and a growing field of specialty companies developing stem cell-derived cardiac models (e.g., Ncardia, FUJIFILM Cellular Dynamics) and organ-on-a-chip platforms (e.g., Emulate, Mimetas). Differentiation lies in the fully integrated, automated workflow from tissue to data.

More companies in Digital Health & Biotech SaaS →More companies in Germany →